178 related articles for article (PubMed ID: 28025966)
1. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
[TBL] [Abstract][Full Text] [Related]
2. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Chen X; Liu D; Wu Y; Song H; Liu Y; Jiang J; Hu P
Xenobiotica; 2017 Jul; 47(7):592-599. PubMed ID: 27560456
[TBL] [Abstract][Full Text] [Related]
3. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.
Mendell J; Tachibana M; Shi M; Kunitada S
J Clin Pharmacol; 2011 May; 51(5):687-94. PubMed ID: 20534818
[TBL] [Abstract][Full Text] [Related]
4. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
7. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
[TBL] [Abstract][Full Text] [Related]
8. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Koretsune Y; Yamashita T; Kimura T; Fukuzawa M; Abe K; Yasaka M
Circ J; 2015; 79(7):1486-95. PubMed ID: 25925842
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria DA; Truitt KE
Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
[TBL] [Abstract][Full Text] [Related]
11. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
12. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.
Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
[TBL] [Abstract][Full Text] [Related]
14. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
15. Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Suzuki S; Morishima Y; Takita A; Yagi N; Otsuka T; Arita T; Yamashita T
Heart Vessels; 2019 Dec; 34(12):2011-2020. PubMed ID: 31123819
[TBL] [Abstract][Full Text] [Related]
16. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
17. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell J; Noveck RJ; Shi M
Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]